Nasal Antisepsis for C. Auris Prevention

Conditions

• Candida Auris Infection
• Colonization, Asymptomatic

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Povidone Iodine Topical — DRUG
  Topical intranasal povidone iodine (10%) twice daily for 5 days

Study Details

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Key Dates

Start date

Jan 29, 2024

Status verified

Oct 2025

Primary completion

Dec 31, 2026

Completion

Dec 31, 2028

Study Design

Enrollment

120 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Active Comparator: Intranasal Povidone Iodine
  Nasal iodophor applied twice daily for five days.
• No Intervention: Control
  Routine care.

Primary Outcome Measure

Detection of C. auris from the anterior nares [ Time Frame: Through study completion and data analysis in three years (2028) ]

Central Contacts

• Sarah E. Sansom, DO
  3125636201
  [email protected]
• Mary K. Hayden, MD
  3129428727
  [email protected]

Locations (3)

Find similar trials in Chicago, IL